MAOBMonoamine Oxidase Type B (Parkinson's disease medication)
MAOBMaster of Arts in Organizational Behavior (various schools)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Regarding clinical and histopathological parameters of tumor we did not find statistical significance between reduced expression of CYP27A1, CYP2E1, CYP2R1, CYP2J2, CYPU1, CYP4F12, CYP4X1, CYP4B1, PTGIS, ALOX12, and MAOB genes and increased expression of CYP27B1 gene with tumor extension, nodal metastasis, and tumor progression in OSCC development.
Finally, the genes related to the inactivation of 5-HT present low expression of the gene that codes for the expression of MAOA is seen in all structures, while the gene that codes for the monoamine oxidase enzyme MAOB has medium expression in the thalamus and low expression in the hypothalamus, midbrain, and pons (Figure 2 Supplementary).
In this study, biological oxidation was determined to be the most significant pathway, which includes the upregulation of Aoc1, BC021614, Cyp17a1, Cyp27b1, Cyp2d22, Cyp2d26, Cyp4a14, Ephx1, Gm10639, Gm3776, Gsto1, Maoa, and Maob and downregulation of Ces2c, Cndp2, Cyp2a4, Cyp51, and Cyp7b1.
MAO-A and MAOB activities were determined by fluorometric kynuramine deamination assay set up in 384-well solid white flat-bottom plates [20].
MAOA and MAOB polymorphisms and anger-related traits in suicidal participants and controls.
The team demonstrated that treating these mice with modelled Alzheimer's disease with a MAOB inhibitor fully recovered the mice's memory.
We found that AFA-PC inhibited MAOB activity in a dose-dependent manner with a [IC.sub.50] value equal to 1.33 [micro]M, the [IC.sub.50] value of the positive control deprenyl was 0.28 [micro]M.
The Management of Early Parkinson's disease (11) includes adjuvant therapy to levodopa with a dopamine agonist, a MAOB inhibitor or a catechol-O-methyl transferase (COMT) inhibitor (Table 3).
Compared with the control groups (either placebo or levodopa at study onset), the MAOB group (either alone or withlevodopa) showed significant improvement on the motor section (weighted mean difference [WMD]=-3.81 on a 108-point scale; 95% CI, -5.36 to -2.27) and activities of daily living section (WMD=-1.50 on a 52-point scale; 95% CI, -2.53 to -0.48).
Other physiological changes in CDS include changes in neurotransmitters, increased levels of free radicals and increased levels of monoamine oxidase B (MAOB), a crucial enzyme, in the brain.
(15), (62) MAOB inhibitors (eg, selegiline, rasagiline) reduce breakdown of dopamine in the brain, thus increasing the supply of dopamine.